caring for foot/ankle disorders that require immobilization. They instead recommended that patients be risk stratified by their provider and have a VTED prevention plan (which could include the use of LMWH) tailored to their individual risk level (13, 16, 17) . Because it is well known that the rate of VTED varies greatly after foot/ankle surgery (e.g., the rate of distal, asymptomatic DVT varies anywhere from 2% with hallux valgus surgery (18) to as much as 36% after Achilles tendon surgery (19) ), we postulated that, similar to hip and knee replacement surgery, the decision to provide chemical prophylaxis, from a strictly costeffectiveness perspective, might be entirely explained by the type of foot/ankle surgery, regardless of patient-specific factors (e.g., medications, comorbidities, personal history; Fig. 1 ).
Cost-effectiveness analyses (CEAs) are useful tools for determining which of ≥2 competing strategies would be the best allocation of resources. In a CEA, health effects can be measured in natural units of outcome (e.g., the number of deaths) or the value individuals place on their health (e.g., quality-adjusted life-years [QALYs] ). QALYs estimate a patient's health-related quality of life and their length of life in a less than perfect state of health. QALYs are useful for determining the cost-effectiveness of competing strategies because they act as a common measure of health benefits and account for such things as mortality and morbidity. Specifically, cost per QALY estimates allow for a comparison between different healthcare interventions that compete for the same pool of resources (20, 21) . To the best of our knowledge, no study has focused on the costs and health effects of VTED prophylaxis with LWMH after foot and ankle surgery. In the present study, we conducted a CEA to assess whether routine prophylaxis with LMWH after foot and ankle surgery would be a good use of resources, irrespective of patient factors.
Materials and Methods

Overview
A decision tree model using a cohort approach was built in TreeAge Pro Healthcare 2014 (TreeAge Software, Inc., Williamstown, MA). The model was used to conduct a CEA that compared the costs and outcomes of implementing LMWH as a form of chemical DVT prophylaxis versus the strategy of implementing no prophylaxis after foot and ankle surgery. The 2 strategies, prophylaxis with LMWH versus no prophylaxis, were compared in 5 different surgical scenarios: Achilles tendon repair (ATR), total ankle arthroplasty (TAA), hallux valgus surgery (HVS), hindfoot arthrodesis (HA), and ankle fracture surgery (AFS).
For each surgical scenario, the 2 strategies were compared in terms of 2 outcomes: incremental healthcare costs and incremental QALYs. The 2 outcomes were combined in the form of incremental cost-effectiveness ratios (ICERs). We calculated the short-and long-term results; short-term results were the 1-year outcomes and longterm results were the lifetime outcomes. Costs were evaluated from the healthcare system perspective and are expressed in 2015 U.S. dollars. For the long-term analysis, future costs and QALYs were discounted at a 3% annual rate in accordance with recommendations provided by the U.S. Public Health Service and consistent with other CEAs.
Decision Tree Model
Structure
The decision tree model is presented in Fig. 2 . Patients receiving no prophylaxis had several health effects possible, including no event, asymptomatic DVT, symptomatic DVT, or pulmonary embolism (PE). In the case of an asymptomatic DVT, our model allowed for 2 likely outcomes: resolution or mild postthrombotic syndrome (PTS). In the case of symptomatic DVT, 5 potential outcomes were included: resolution, PTS, major hemorrhage, recurrent DVT, or subsequent PE. A patient with PTS could have developed either the mild or severe form of PTS after symptomatic DVT. A patient with major hemorrhage either died or the condition resolved. After recurrent DVT, the condition either resolved or the patient experienced a major hemorrhage due to treatment. After a subsequent PE, the possible outcomes were death, chronic pulmonary hypertension (HTN), major hemorrhage due to treatment, or resolution with treatment. In the prophylactic strategy, in addition to the conditions occurring with no prophylaxis, patients were also at risk of major hemorrhage and symptomatic heparin-induced thrombocytopenia (HIT) due to prophylaxis with LMWH. Patients undergoing any of those 2 conditions either had resolution with treatment or died.
Surgical Scenarios and Events
We selected several surgeries known to be associated with an increased VTED risk (i.e., ATS, AFS, HA, TAA) (16, 17, 22) and also a common foot surgery (HVS) to model. We considered only outcomes and events that had received frequent enough attention in the published data to be able to calculate summary probabilities. Although less commonly reported, we also considered the costs and health effects associated with PTS. PTS can develop after DVT, and those affected can present for treatment of leg pain and swelling (23) . PTS can affect 20% to 50% of patients diagnosed with DVT, and the clinical manifestations can occur within 2 years of the inciting event (24) . For those living with PTS, especially the severe form of disease, it can lead to a diminished quality of life (25) . The severe form of PTS typically includes venous leg ulcers, which Risk factors for deep venous thrombosis after foot and ankle surgery can be divided into 1 of 3 categories generally-patient specific, treatment specific, and surgery specific. Although none of the surgery-specific factors in the far right column identified in the recent American College of Foot and Ankle Surgeons clinical consensus statement reached the level of a primary risk factor, the present study tested this assumption using direct costs and utilities as outcomes. Reprinted, with permission, from Fleischer et al (16) . substantially increase treatment costs and can affect 5% to 10% of patients with PTS (23, 24) . In the present analysis, we chose to consider both mild and severe forms of PTS.
Data Inputs and Assumptions
The decision tree model base case parameters and sources are summarized in Tables 1 and 2 . The rates and probability of each health effect (tree node) were derived from the available data. Summary estimates were used when >1 source was available. Direct costs were derived from the reported data, drug manuals, and the Centers for Medicare and Medicaid. All costs were adjusted to reflect U.S. dollar 2015 rates. The costs associated with each health effect included both diagnostic costs and treatment costs (e.g., outpatient and inpatient costs, pharmacologic treatment, and disease management).
In the present analysis, we assumed maximal benefit and least harm with LMWH use. As such, we assumed that the asymptomatic and symptomatic DVT rate would both be reduced by 0.51 with LMWH use and the PE rate would be reduced to 0 (42) . Similarly, we assumed the fewest possible side effects resulting from LMWH use, using the lowest reported rates of HIT and major hemorrhage from the published data, and we did not consider the negative health effects and costs associated with minor hemorrhage (i.e., minor hemorrhage rate = 0).
For the long-term analysis, our base case assumption for ATR, AFS, and HVS was a 45-year-old female. This was based on the approximate age and gender of patients typically undergoing these surgeries (8, 11, 29, 55) . Similarly, the base case assumption we used for TAA and HA was a 60-year-old female (8, 56) . Although some procedures (e.g., ATR, TAA) did not demonstrate a clear gender predilection, we chose a female patient for each scenario because females live longer than males. We rationalized that if providing prophylaxis is not cost-effective in preventing the long-term complications of VTED over the lifetime of a female patient, it would also not be cost-effective for a male patient with a shorter lifespan. Other than age and gender (which was required for longterm cost estimates and utilities), no other patient factors (e.g., personal history of VTED, oral contraceptive use) were considered in the analysis. This was to ensure that we answered our primary question of whether surgery alone can drive the decision to use LMWH. The duration of prophylaxis with LMWH varied in the reported data, with few clear guidelines. Prophylaxis in the present analysis consisted of enoxaparin 40 mg once daily for 4 weeks postoperatively to allow for a period of immobilization. For resolution of a first symptomatic DVT, we assumed treatment with enoxaparin for 7 days at 80 mg twice daily, followed by subsequent use of warfarin for 3 months (57). For a second symptomatic DVT, we assumed treatment with enoxaparin 80 mg twice daily, followed by warfarin for 6 months, although less clarity is available for the approach to treatment of recurrent VTED, and indefinite anticoagulation can be used (58) . Utilities for health events were used to calculate the QALYs. Utilities are weights representing the quality of life on a standard 0 to 1 scale. Although the short-term analysis considers 1-year costs and utilities, the long-term analysis considers lifetime costs and utilities to account for chronic conditions associated with the development of VTED. To calculate life expectancy, the long-term analysis assumed a 45-year-old female cohort for ATR, AFS, and HVS and a 60-year-old female cohort for TAA and HA. For the longterm analysis, only chronic pulmonary HTN was found to have a long-term impact on utilities estimates. The long-term management of severe PTS, mild PTS, and chronic pulmonary HTN was considered in the calculation of lifetime costs.
Analysis Outcomes
The expected health outcomes were the number of QALYs and costs associated with each strategy. To calculate the QALYs associated with each strategy, utilities were attached to each health event and multiplied by the probability of each event, by "rolling back" the decision tree. Performing the calculation for each node and working from the last decision in the sequence to the first constituted "rolling back" the decision tree. The total cost of each strategy was calculated by associating a cost to each health event and multiplying the probability of each event by the associated cost, again by "rolling back" the decision tree.
Cost-Effectiveness Analysis
ICERs were estimated. The ICER represents the additional cost to achieve 1 additional QALY and is computed by dividing the difference in total costs by the difference in total QALYs associated with each strategy. The preferred strategy is determined by comparing the ICER to what decision makers are willing to pay for an additional QALY. A strategy is considered cost-effective if the ICER is not more than the decision maker's intrinsic valuation for an additional QALY (20, 21) . No consensus has been reached on decision makers' willingness to pay in the United States, although a $50,000/QALY benchmark has been used in several studies (59, 60) .
Sensitivity Analysis
One-way sensitivity analyses were conducted to estimate the effect of changing key parameters individually on the cost-effectiveness results. The sensitivity analysis tested a range of values for all cost and utility parameters and for 4 selected probabilities: the probability of death from hemorrhage, the probability of death from HIT, the probability of hemorrhage due to prophylaxis, and the probability of HIT due to prophylaxis. Those 4 probabilities were selected because they were the probabilities for which a (45) did not specify the price year; 2004 assumed. § Chronic condition: cost applied to every year for remainder of the patient's life, with discounted rate applied after year 1. || Cost of treatment for DVT plus cost of treatment with warfarin for 3 additional months. ¶ 2010 life expectancy for a 45-year-old male and female was 33.9 years and 37.7 years, respectively (54); thus, rationale for selecting female gender in the present study was that the life expectancy is longer for females.
# Utility reported by Lenert and Soetikno (51) was adjusted for U.S. population normal value of 0.87 and recalculated for 1 year based on the duration of condition of 0.86 year reported by Caprini et al (44) ; for remaining years, utility of 0.87 applied. ** Utility reported by Lenert and Soetikno (51) was adjusted for U.S. population normal value of 0.87 and recalculated for 1 year; for remaining years, utility of 0.87 applied.
† † Calculated QALYs using U.S. population norm of 0.87 with the time with the condition as reported by Hogg et al (53) as 1 month with PE or DVT symptoms and calculated for 1 year; for remaining years, utility of 0.87 applied.
‡ ‡ Assuming the rate used was for gastrointestinal hemorrhage, QALYs calculated using U.S. population norm of 0.87 and the time with the condition as reported by Hogg et al (53) as 1 week with symptoms. § § Assumption: average of mild PTS and PE resolution utilities.
greater effect of prophylaxis with LMWH would be expected. Variations to costs were taken from reported values. When not available from the reported data, the sensitivity analysis used a 20% variation from the base case. For utilities, the upper and lower values of the range were informed by the 95% confidence interval or the interquartile range reported in the study from which the base case value was taken. Sensitivity analysis of the probabilities selected considered the double of the base case for the upper value and 0 probability for the lower value.
Results
Short-Term Analysis
The results from the short-term analysis can be found in Table 3 . For ATR, compared with not performing prophylaxis, prophylaxis with LMWH cost on average $745 more and was associated with small QALY gains (0.002). This resulted in an ICER of $329,656, well above the commonly accepted $50,000/QALY threshold. Therefore, for ATR, the low incremental QALY gained with prophylaxis did not justify the additional cost, and prophylaxis with LMWH would not be a costeffective use of resources.
For TAA, compared with not performing prophylaxis, prophylaxis with LMWH cost on average $664 more and was associated with small QALY gains (0.003). This resulted in an ICER of $249,669, well above the $50,000/QALY threshold. Therefore, for TAA, the low incremental QALY gained associated with prophylaxis did not justify the additional cost and prophylaxis with LMWH would not be a costeffective use of resources.
For HVS, compared with not performing prophylaxis, prophylaxis with LMWH cost on average $1045 more and was associated with a small QALY loss. Therefore, for HVS, an ICER was not computed because the no-prophylaxis option dominated the prophylaxis option, and prophylaxis with LMWH would not be a cost-effective use of resources.
For HA, compared with not performing prophylaxis, prophylaxis with LMWH cost on average $1020 more and was associated with very small QALY gains. This resulted in an ICER of $76,778,968, well above the $50,000/QALY threshold. Therefore, HA prophylaxis with LMWH would not be a cost-effective use of resources.
For AFS, compared with not performing prophylaxis, prophylaxis with LMWH cost on average $906 more and was associated with small QALY gains (0.002). This resulted in an ICER of $425,082, well above the $50,000/QALY threshold. Therefore, for AFS, the low incremental QALY gained associated with prophylaxis did not justify the additional cost, and prophylaxis with LMWH would not be a cost-effective use of resources.
Long-Term Analysis
The results of the long-term (or lifetime) analysis can be found in Table 4 .
For ATR, prophylaxis with LMWH was associated with slightly lower long-term costs, such that not performing prophylaxis cost $126 more over the lifetime of the individual. However, not providing LMWH prophylaxis was associated with significantly greater QALY (0.94). For ATR, not performing prophylaxis was therefore very cost-effective, with an ICER of $134.
For TAA, prophylaxis with LMWH was associated with slightly lower long-term costs, such that not performing prophylaxis cost $108 more. However, not performing prophylaxis was associated with significantly greater QALY (1.04). For TAA, not performing prophylaxis was therefore very cost-effective, with an ICER of $104.
For HVS, compared with not performing prophylaxis, prophylaxis with LMWH cost on average $1013 more and was associated with QALY losses (−0.05). Therefore, for HVS, an ICER was not computed because the no-prophylaxis option dominated the prophylaxis option, and prophylaxis with LMWH would not be a cost-effective use of resources.
For HA, compared with not performing prophylaxis, prophylaxis with LMWH cost on average $972 more and was associated with QALY losses (−0.33). Therefore, for HA, an ICER was not computed because the no-prophylaxis option dominated the prophylaxis option, and prophylaxis with LMWH would not be a cost-effective use of resources.
For AFS, compared with not performing prophylaxis, prophylaxis with LMWH cost on average $271 more and was associated with QALY losses (−0.4). Therefore, for AFS, an ICER was not computed because the no-prophylaxis option dominated the prophylaxis option, and prophylaxis with LMWH would not be a cost-effective use of resources.
Sensitivity Analyses
In the short-term analysis for ATR and TAA, the only variable that affected the results was the cost of LMWH. Holding all other variables constant, prophylaxis with LMWH after ATR and TAA would become a cost-effective use of resources when the cost of LWMH decreased to <$400. The results were robust to changes in the other variables. For AFS, similarly, the only variable with an effect on the results was the cost of prophylaxis with LMWH. Holding all other variables constant, for a cost of LWMH <$100, prophylaxis with LMWH for AFS would be a cost-effective use of resources. The results were Abbreviations: AFS, ankle fracture surgery; ATR, Achilles tendon repair; HA, hindfoot arthrodesis; HVS, hallux valgus surgery; ICER, incremental cost-effectiveness ratio; LMWH, low-molecular-weight heparin; QALY, quality-adjusted life-year; TAA, total ankle arthroplasty. * Costs in U.S. dollars at a 2015 price base. Abbreviations: AFS, ankle fracture surgery; ATR, Achilles tendon repair; HA, hindfoot arthrodesis; HVS, hallux valgus surgery; ICER, incremental cost-effectiveness ratio; LMWH, low-molecular-weight heparin; QALY, quality-adjusted life-year; TAA, total ankle arthroplasty. * Costs and QALYs discounted at 3% annual rate; costs in U.S. dollars at a 2015 price base (base case assumed 45-year-old female cohort for ATF, AFS, and HVS and 60-yearold female cohort for TAA and HA).
robust to changes in the other variables. For both HA and HVS, the short-term base case results were robust to sensitivity analyses. No circumstances were found in which prophylaxis was cost-effective for HA and HVS. For the long-term analysis, the results were robust in all sensitivity analyses. No circumstances were found in which prophylaxis was cost-effective when the long-term costs and effects were considered.
Discussion
Similar to several recently reported guidelines written primarily with the individual in mind (13, 16, 17, 61) , the results of our analysis, which represent the healthcare system's perspective, also discourage a strategy of routine LMWH prophylaxis after foot/ankle surgery. This was true for the short-and long-term analyses both for all 5 surgeries. These findings should be of interest when developing broad clinical guidelines and algorithms that consider healthcare appropriation and cost containment with healthcare policy.
The short-term analysis showed that prophylaxis with LMWH was always associated with higher costs, which were mainly driven by the cost of prophylaxis. For ATR, TAA, HA, and AFS, prophylaxis was associated with slightly better health outcomes. However, the gain in QALYs was too small to justify the additional investment in prophylaxis with LMWH. Therefore, for those 4 surgery scenarios, prophylaxis was not cost effective, with the ICER well above the $50K threshold. For HVS, in addition to being more costly, prophylaxis was associated with worse health outcomes and, therefore, was dominated by not performing prophylaxis.
For HVS, compared with no prophylaxis, prophylaxis was associated with a QALY loss because the reduction in the probability of DVT and, therefore, of the utility losses associated with DVT, was not large enough to overcome the utility loss associated with major hemorrhage and symptomatic HIT caused by prophylaxis with LMWH. This is related to extremely low probabilities of asymptomatic and symptomatic DVT after HVS. Similarly, for HA, the very low probabilities of asymptomatic and symptomatic DVT after HA led to practically undistinguishable QALYs between prophylaxis and no prophylaxis. For ATR, TAA, and AFS, the utility loss associated with complications of LMWH prophylaxis was superseded by the utility gains derived from a lower risk of DVT. However, the modest gains (as seen by the ICER for each of these 3 surgeries well above the $50,000/QALY threshold) made routine use of LMWH an undesirable strategy from a costeffectiveness perspective.
The long-term analysis showed that prophylaxis with LWMH was associated with worse health outcomes for the 5 surgical scenarios. For ATR and TAA, prophylaxis was associated with slightly lower longterm costs (<$200 less per patient over a lifetime). For HVS, HA, and AFS, prophylaxis cost more over the long term.
In the long term for both ATR and TAA, compared with no prophylaxis, prophylaxis with LMWH showed a greater decrease in the costs. This can be explained by the sufficient decrease in the probability of conditions that require long-term management (mild or severe PTS and pulmonary HTN) to justify the cost of prophylaxis. However, prophylaxis with LMWH was also associated with lower QALYs, mainly because the QALYs gained due a lower probability of conditions with a long-term impact on health utility (pulmonary HTN) did not overturn the QALYs lost in association with symptomatic HIT and major hemorrhage due to LMWH. For those 2 surgeries, an ICER was computed because no prophylaxis was more expensive but was also associated with better health outcomes. The low ICER associated with no LMWH prophylaxis ($104 to $126 per QALY) supports a strategy that does not routinely use LMWH for prophylaxis after ATR and TAA surgery.
For HVS, HA, and AFS, prophylaxis with LMWH was more expensive than no prophylaxis over the lifetime because the lower costs associated with lower probabilities due to conditions that require longterm management (mild or severe PTS and pulmonary HTN) did not justify the added cost of prophylaxis. Prophylaxis with LMWH was associated with lower QALYs because the QALYs gained from a lower probability of conditions with a long-term impact on health utility (pulmonary HTN) did not overturn the QALYs lost in association with symptomatic HIT and major hemorrhage due to LMWH.
The findings of the present study, therefore, argue against the routine use of LMWH prophylaxis from a cost-effectiveness vantage point. Instead, we believe our findings highlight the importance of risk stratification for individual patients according to their unique characteristics (e.g., personnel history of VTED, obesity) and postoperative course and not performing prophylaxis solely based on the type of foot and ankle surgery performed. This stance is consistent with the American College of Foot and Ankle Surgeons Clinical Consensus Statement on the risk and prevention of VTED and is also consistent with other recent guidelines (13, 16, 17, 61) . Although these guidelines were written primarily with the healthcare provider and individual patient in mind, our findings, which focused on the health outcomes and economics of the healthcare system, are actually quite complimentary and in support of these guidelines. Careful determination of the need for LMWH prophylaxis after foot and ankle surgery should be performed on a case-by-case basis.
It is important to consider the findings of the present analysis within the context of its limitations. We purposely did not factor additional patient-specific risk factors into this analysis and instead only a base case scenario (age and gender) for each surgery. This was done to determine whether the surgery (and the circumstances surrounding the surgery) would be enough, in and of itself, to drive the decision to provide LMWH prophylaxis. It is important to recognize, therefore, that the findings of the present CEA can only be generalized to the base case scenario, which was essentially a patient with a moderate risk of VTED based on the average participant in the studies used to derive VTED event probabilities (Table 1) . It is very likely that if we considered the base case to be an elderly patient presenting with a personal history of VTED and morbid obesity (high risk of VTED), we would have concluded that a strategy that favors routine LMWH is actually cost-effective for the health system for many of the surgeries we examined.
Another limitation in the present study that our results will not necessarily be generalizable to other forms of chemical prophylaxis. We chose to consider LMWH because it is currently the most widely used chemical agent for VTED prophylaxis in the United States. However, newer agents that can be taken by mouth and do not require blood monitoring (e.g., apixaban) with a lower potential risk of bleeding are becoming increasingly more available. Furthermore, our shortterm conclusions were heavily dependent on the cost of LMWH and might change if or when LMWH becomes less expensive. Our findings could also be less generalizable to health systems outside the United States, where the cost of LMWH therapy might be less. A similar study conducted in those systems might reach alternate conclusions.
Other limitations and considerations arise from the assumptions that were made. One such assumption is the length of VTED prophylaxis after surgery. Surgeons, for example, might choose to perform prophylaxis for their patient for a shorter or longer period than the 4 weeks used in our analysis. This CEA also assumed maximal efficacy of LMWH for event probabilities not available in the reported data. New evidence has actually suggested LMWH might be less effective at preventing VTED after lower extremity injury/surgery than previously thought (62) . This new evidence, however, only strengthens our conclusions that routine use of LMWH should not be recommended after foot/ankle surgery. Finally, our analysis considered only the direct healthcare costs associated with the 2 competing strategies and did not factor in the effect of indirect costs.
In conclusion, assuming maximal efficacy and minimal harm with LMWH use, we did not find any foot/ankle surgical condition for which routine prophylaxis would be preferred from the healthcare system standpoint. Unlike hip and knee replacement surgery, the decision to use LMWH prophylaxis should not be determined solely by the type of foot/ankle surgery planned. Patient-specific risk factors (e.g., personal history of VTED, comorbidities) and/or prolonged ankle immobilization (16) will continue to drive the decision to provide chemical prophylaxis.
